Mechanisms of tolerance to DNA damaging therapeutic drugs

Carcinogenesis

Volumn 22, Issue 12, 2001, Pages 1931-1937

  Karran, Peter ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENZO[A]PYRENE; BUSULFAN; CARBOPLATIN; CISPLATIN; DNA; DOXORUBICIN; ETOPOSIDE; FLOXURIDINE; FLUOROURACIL; MESYLIC ACID METHYL ESTER; N ACETOXY N (2 FLUORENYL)ACETAMIDE; OXIDIZING AGENT; TIOGUANINE;

ARTICLE; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DNA METHYLATION; DRUG MECHANISM; DRUG TOLERANCE; HUMAN; HUMAN CELL; IONIZING RADIATION; MISMATCH REPAIR; MULTIDRUG RESISTANCE; PHENOTYPE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 0035687887     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/22.12.1931     Document Type: Article

References (69)

1. Mammalian DNA mismatch repair
2. The barrier to recombination between Escherichia coli and Salmonella typhimurium is disrupted in mismatch-repair mutants
3. 1 arrest in human cancer cells
4. Inactivation of the mouse Msh2 gene results in postreplicational mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to tumorigenesis
5. Increased somatic recombination in methylation tolerant cells with defective mismatch repair
6. Repair of double-strand breaks by homologous recombination in mismatch repair-defective mammalian cells
7. DNA damage tolerance, mismatch repair and genome instability
8. CCNU-sensitivity in mismatch repair defective human cells
9. An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair
10. 6-methylguanine residues in Escherichia coli DNA
11. - mutants of Escherichia coli: A role for 6-methyladenine in mutation avoidance
12. + revertants and suppressor mutations that modify secondary phenotypes of dam-3 strains of Eschericia coli
13. Mismatch repair in correction of replication errors and processing of DNA damage
14. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine
15. The role of DNA mismatch repair in drug resistance
16. The role of mismatch repair in DNA damage-induced apoptosis
17. Mismatch repair of cis-diamminedichloroplatinum(II)-induced DNA damage
18. Recombination is essential for viability of an Escherichia coli dam (DNA adenine methyltransferase) mutant
19. Multiple pathways of recombination define cellular responses to cisplatin
20. Mismatch repair proteins MutS and MutL inhibit RecA-catalysed strand transfer between diverged DNAs
21. 4-methylthymine, or the cisplatin-d(GpG) adduct
22. 6-methylguanine induces intrachromosomal homologous recombination in human cells
23. Dependence on RAD52 and RAD1 for anticancer drug resistance mediated by inactivation of mismatch repair genes
24. 6-methylguanine-DNA methyltransferase-deficient yeast cells
25. DNA mismatch binding and incision at modified guanine bases by extracts of mammalian cells: Implications for tolerance to DNA damage
26. 6-methylthioguanine
27. hMutSα- and hMutLα-dependent phosphorylation of p53 in response to DNA methylator damage
28. Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins
29. Mismatch repair processing of carcinogen-DNA adducts triggers apoptosis
30. Human MutSα specifically binds to DNA containing aminofluorene and acetylaminofluorene adducts
31. Replication inhibition and translesion synthesis on templates containing site-specifically placed cis-diamminedichloroplatinum(II) DNA adducts
32. All three SOS-inducible DNA polymerases (Pol II, Pol IV and Pol V) are involved in induced mutagenesis
33. N-2-aminofluorene and N-2 acetylaminofluorene adducts: The local sequence context of an adduct and its chemical structure determine its replication properties
34. 4-alkylthymine and the mutagenic properties of these bases
35. RuvAB acts at arrested replication forks
36. Spontaneous development of drug resistance: Mismatch repair and p53 defects in resistance to cisplatin in human tumor cells
37. Self-destruction and tolerance in resistance of mammalian cells to alkylation damage
38. Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents
39. DNA mismatch binding defects, DNA damage tolerance, and mutator phenotypes in human colorectal carcinoma cell lines
40. Evidence for a connection between the mismatch repair system and the G2 cell cycle checkpoint
41. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation
42. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage
43. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage
44. Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N′-nitro-N-nitrosoguanidine
45. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability
46. Growth inhibition due to complementation of transforming growth factor-β receptor type II-defect by human chromosome transfer in human colorectal carcinoma cells
47. Reversal of in vivo drug resistance by the transforming growth factor-β inhibitor decorin
48. Cisplatin-resistant derivatives of murine L1210 leukemia cells are not susceptible to growth-inhibiting and apoptosis-inducing actions of transforming growth factor-β1
49. 6-methylguanine and 6-thioguanine cytotoxic effects: A cross-resistant phenotype in N-methylnitrosourea-resistant Chinese hamster ovary cells
50. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft
51. Separation of killing and tumorigenic effects of an alkylating agent in mice defective in two of the DNA repair genes
52. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines
53. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells
54. Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: Spontaneously mutant selection
55. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen
56. Characterization of the p53 tumor supressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
57. Cisplatin and adriamycin resistance are associated with MutLα and mismatch repair deficiency in an ovarian tumor cell line
58. Single step selection of cis-diamminedichloroplatinum(II) resistant mutants from a human ovarian carcinoma cell line
59. Mismatch repair and p53 independently affect sensitivity to N-(2-chloroethyl)-N′-cyclohexyl-N-nitrosourea
60. Cytotoxic and mutagenic response of mismatch repair-defective human cancer cells exposed to a food-asociated heterocyclic amine
61. Carcinogen-specific induction of genetic instability
62. Reduced MLH1 expression in breast tumors after primary chemotherapy predicts disease-free survival
63. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy
64. Mismatch repair defects as a cause of resistance to cytotoxic drugs
65. p53 interacts with the DNA mismatch repair system to modulate the cytotoxicity and mutagenicity of hydrogen peroxide
66. Cellular resistance and hypermutability in mismatch repair-deficient human cancer cell lines following treatment with methyl methanesulfonate
67. Differential growth inhibition by 5-fluorouracil in human colorectal carcinoma cell lines
68. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses